Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 13/20 | 0.54 |
| ▸ | F2 | P00734 | 6/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740664 | 0.90 | PSMB5 (0.66) | PSMB5F2PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL4337244 | 0.88 | F2 (0.52) | PSMB5F2PSEN1PSEN2APH1B | |
| SCHEMBL4334543 | 0.87 | F2 (0.50) | PSMB5F2PSEN1PSEN2APH1B | |
| SCHEMBL3751159 | 0.86 | PSMB5 (0.68) | PSMB5F2PSEN1PSEN2APH1B | |
| SCHEMBL3756696 | 0.85 | PSMB5 (0.60) | PSMB5F2PSEN1PSEN2APH1B | |
| SCHEMBL4343744 | 0.82 | PSMB5 (0.59) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3748205 | 0.82 | PSMB5 (0.59) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3746274 | 0.80 | PSMB5 (0.65) | PSMB5F2PSEN1PSEN2APH1B | |
| SCHEMBL20400476 | 0.79 | PSMB5 (0.75) | PSMB5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20400473 | 0.79 | PSMB5 (0.75) | PSMB5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885F2 4790/4885PSEN1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.